军医进修学院学报2012，Vol.33Issue(4)：319-321,324,4.
索拉非尼联合TACE治疗晚期原发性肝癌的临床观察
Effect of combined Sorafenib and transarterial chemoembolization on advanced primary hepatocellular carcinoma
摘要
Abstract
Objective To observe the effect and side effects of combined Sorafenib and transarterial chemoembolization (TACE) on advanced primary hepatocellular carcinoma (HCC). Methods Therapeutic effects of combined oral Sorafenib and TACE for over 1 month on advanced primary HCC in 65 patients admitted to our hospital were retrospectively analyzed according to the RECIST criteria and the side effects were recorded. Results The overall survival rate of the patients was 66.2%. Among the 43 survived patients, HCC was stable in 31 and partially remitted in 7, with a disease control rate of 88.4% and an adverse reaction rate of 78.5%. The disease was significantly relieved after expectant treatment. Conclusion Combined Sorafenib and TACE therapy is safe and effective for advanced primary HCC.关键词
索拉非尼/经导管肝动脉化疗栓塞/原发性肝癌Key words
sorafenib/ transcatheter arterial chemoembolization/ primary liver cancer分类
临床医学引用本文复制引用
崔瀚之,戴广海,石燕,陈丽..索拉非尼联合TACE治疗晚期原发性肝癌的临床观察[J].军医进修学院学报,2012,33(4):319-321,324,4.基金项目
2010年北京市首都特色临床医学技术发展研究项目(Z090507017709017) （Z090507017709017）
